First time in the world, backed by human clinical trials, the GLYCOSA device combines multilayered AI and innovative sensors to monitor blood glucose without the blood sample/needle prick, and with high accuracy in humans.
Our technology provides differentiated value by measuring the glucose directly from the blood in veins and capillaries.
Resolved Painpoints:
A. No painful needle pricks
B. Eliminate higher costs of replenishing supplies such as test-strips and CGM sensors
C. Eliminate the LAG time in Blood Glucose measurements with CGM’s
We tested our device on human subjects by partnering with laboratories for two years. During this time we have performed more than 7000 clinical tests on human patients. The average accuracy of the lastest version of our device is ~ 88.5% (or ~ 11.5% - Mean Absolute Percentage Error (MAPE)).
Pradeep Karla, Ph.D., Stanford LEAD (CEO)
Our team was founded by a group of creative and entrepreneurial people to improve quality of life and patient care through continuous non-invasive monitoring of blood glucose.
For this reason, this group has conducted extensive tests and studies in the field since 2019 and has succeeded in designing accurate blood glucose measuring devices with affordable prices and unique features. The clinical trial of our device has now been completed, and we are prepared to launch our brand in the global market as a brand with distinctive technology and high accuracy for the first time in the world.
Copyright © 2024 GLYCOSA - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.